Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ruff

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Expert Review of Anticancer Therapy|April 18, 2020
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic developmentMichael Ruff, Sani Kizilbash, Jan Buckner
The Journal of Hand Surgery|March 5, 2011
Wrist ganglionsJonathan Gant, Michael Ruff, Brian A Janz
Oncotarget|December 6, 2018
Correction: Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structuresBassil Dekky, Michael Ruff, Dominique Bonnier, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|November 21, 2013
Basilar artery thrombus vs. fenestration: a differential diagnostic challenge in acute ischemic strokePaola Palazzo, Michael Ruff, Michael J Lyerly, et al.
Oncotarget|May 17, 2018
Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structuresBassil Dekky, Michael Ruff, Dominique Bonnier, et al.
Current Treatment Options in Oncology|December 16, 2022
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell TherapyShannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, et al.
Nanomedicine (London, England)|September 5, 2012
Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic differenceRobert K Delong, Azure Risor, Masaaki Kanomata, et al.
The Lancet. Oncology|November 21, 2024
Short-course hypofractionated proton beam therapy, incorporating <sup>18</sup>F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trialSujay Vora, Deanna Pafundi, Molly Voss, et al.
Cell Death & Disease|April 13, 2024
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrP<sup>C</sup>-CCR5 dependent pathwayMarina I Oliveira da Silva, Miguel Santejo, Isaac W Babcock, et al.
International Journal of Radiation Oncology, Biology, Physics|March 27, 2021
Initial Results of a Phase 2 Trial of <sup>18</sup>F-DOPA PET-Guided Dose-Escalated Radiation Therapy for GlioblastomaNadia Nicole Laack, Deanna Pafundi, S Keith Anderson, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Review of Anticancer Therapy|April 18, 2020
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic developmentMichael Ruff, Sani Kizilbash, Jan Buckner
The Journal of Hand Surgery|March 5, 2011
Wrist ganglionsJonathan Gant, Michael Ruff, Brian A Janz
Oncotarget|December 6, 2018
Correction: Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structuresBassil Dekky, Michael Ruff, Dominique Bonnier, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|November 21, 2013
Basilar artery thrombus vs. fenestration: a differential diagnostic challenge in acute ischemic strokePaola Palazzo, Michael Ruff, Michael J Lyerly, et al.
Oncotarget|May 17, 2018
Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structuresBassil Dekky, Michael Ruff, Dominique Bonnier, et al.
Current Treatment Options in Oncology|December 16, 2022
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell TherapyShannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, et al.
Nanomedicine (London, England)|September 5, 2012
Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic differenceRobert K Delong, Azure Risor, Masaaki Kanomata, et al.
The Lancet. Oncology|November 21, 2024
Short-course hypofractionated proton beam therapy, incorporating <sup>18</sup>F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trialSujay Vora, Deanna Pafundi, Molly Voss, et al.
Cell Death & Disease|April 13, 2024
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrP<sup>C</sup>-CCR5 dependent pathwayMarina I Oliveira da Silva, Miguel Santejo, Isaac W Babcock, et al.
International Journal of Radiation Oncology, Biology, Physics|March 27, 2021
Initial Results of a Phase 2 Trial of <sup>18</sup>F-DOPA PET-Guided Dose-Escalated Radiation Therapy for GlioblastomaNadia Nicole Laack, Deanna Pafundi, S Keith Anderson, et al.
Pageof 2